Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30830400 | 1.00 | CRBN (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL2173656 | 0.92 | CRBN (0.71) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL2173648 | 0.90 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL2175681 | 0.88 | CRBN (0.80) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL14998787 | 0.84 | CRBN (0.64) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29497779 | 0.84 | CRBN (0.64) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20783221 | 0.83 | CRBN (0.66) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL2173119 | 0.82 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL22007336 | 0.81 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL17174014 | 0.81 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546430-B2 | Thalidomide analogs | P2D, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | claimed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | claimed |
| JP-2007505922-A | — | — | 2007-03-15 | — | — | JP | claimed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | claimed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | claimed |
| EP-3356346-B1 | THALIDOMIDE ANALOGS AND METHODS OF USE | US HEALTH (US) | 2024-11-06 | — | — | EP | disclosed |
| US-11440880-B2 | Thalidomide analogs and methods of use | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-09-13 | — | — | US | disclosed |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-10836721-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836721-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973057-B2 | Thalidomide analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885IKZF3 854/4885 |
| US-10836721-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885IKZF3 854/4885 |
| US-11440880-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.